StoryTest
TUNE-401 shows positive Phase 1b/2a proof-of-concept data for hepatitis B; Phase 2 planned for late 2026
Tune presented Phase 1b/2a data for TUNE-401 at the European Association for the Study of the Liver Congress, showing durable dose-dependent repression of all HBV biomarkers including HBsAg, HBeAg, and HBcrAg. The company plans to initiate Phase 2 development as early as late 2026.
- Phase 1b/2a trial enrolled 19 patients across four dose levels and a multi-dose cohort.
- All HBV biomarkers showed durable, dose-dependent suppression in treated patients.
- Data represents first clinical evidence of epigenetic silencing for hepatitis B.
- Phase 2 initiation planned for late 2026 to confirm efficacy and safety profile.